alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1,301–1,325 of 1,380 studies in Disease mechanisms (page 53 of 56) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Other subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

What “Disease mechanisms” covers

Disease mechanisms — Cell- and molecule-level research into what actually goes wrong in Alzheimer's and related diseases.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Patient‐derived forebrain cortical organoids reveal biphasic tau–MAP6–microtubule axis dysfunction in tauopathy

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Alzheimer s & Dementia 2026-07-01

Early-phase tau mutant organoids showed elevated tau, hyperdynamic microtubules, and neuronal hyperexcitability, partially reversible by tau reduction. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Mechanical stimulation prevents impairment of axon growth and overcompensates microtubule destabilization in cellular models of Alzheimer’s disease and related Tau pathologies

✓ Peer-reviewed alzhub usefulness score 34 out of 100. Frontiers in Medicine 2025-05-14

Alzheimer’s disease (AD) and related tauopathies such as frontotemporal dementia (FTD) or traumatic brain injury (TBI) are neurodegenerative disorders characterized by progressive loss of memory and cognitive function. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

A human iPSC model of Tauopathies engineered for 4R Tau isoform expression endogenously develops late‐stage neuronal Tau pathology

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Alzheimer s & Dementia 2025-12-01

We found that induction of adult human brain-like 4R Tau isoform expression enables endogenous formation of late-stage Tauopathy hallmarks in iPSC-derived neurons engineered to contain synergistic Tau mutations. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

PDE4A knockdown rescues alcohol-induced cognitive impairment and synaptic dysfunction via the cAMP/PKA/CREB pathway

✓ Peer-reviewed alzhub usefulness score 33 out of 100. The International Journal of Neuropsychopharmacology 2026-07-01

This study demonstrated that selectively targeting PDE4A rescued cognitive and neuropathological deficits in a validated mouse model of AlD. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Targeting Metabolic Dysregulation in Alzheimer’s Disease: A Potential Therapeutic Strategy

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Current Drug Metabolism 2025-09-01

Alzheimer's disease (AD), the most common form of dementia, is characterized by progressive cognitive decline and neuropathological hallmarks, including amyloid-beta plaques and tau tangles. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Treatment-resistant patients with focal epilepsy of unknown cause display reduced neurogranin levels: a preliminary study

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Ideggyógyászati Szemle 2025-01-01

Neurogranin levels were significantly reduced in MTLE-HS patients as compared to FLE patients and healthy controls but were not correlated with any of the clinical and cognitive variables. 5 key findings →

Participants: 51 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Extracellular Vesicles in Alzheimer’s Disease: Mechanisms, Immunotherapy Links, and Clinical Translation

✓ Peer-reviewed alzhub usefulness score 33 out of 100. Current Pharmaceutical Design 2026-05-13

Alzheimer disease (AD) is a progressive neurodegenerative disorder characterized by synaptic dysfunction, neuroinflammation, and cognitive impairment. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Role of prion protein in mediating the synaptotoxic effects of tau oligomers: Implications for Alzheimer’s disease and related tauopathies

✓ Peer-reviewed alzhub usefulness score 32 out of 100. Neural Regeneration Research 2025-08-13

We recently confirmed and extended these findings using recombinant TauOs generated from full-length human tau in the presence of arachidonic acid (Balducci et al., 2025; Figure 1). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

2′-Fucosyllactose mitigates cognitive deficits in Alzheimer models: targeting amyloid pathology, oxidative stress, and synaptic plasticity

✓ Peer-reviewed alzhub usefulness score 32 out of 100. Frontiers in Pharmacology 2025-08-21

2′-FL improved cognitive performance in 5xFAD mice, reduced Aβ plaque deposition and pro-inflammatory cytokine levels in vivo , and mitigated oxidative stress and synaptic dysfunction in cellular models. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Pyk2 plays a critical role in synaptic dysfunction during the early stages of Alzheimer’s disease

✓ Peer-reviewed alzhub usefulness score 32 out of 100. Molecular Neurodegeneration Advances 2026-03-07

The locus of the gene PTK2B encoding the tyrosine kinase Pyk2 has been associated with the risk of late-onset Alzheimer’s disease, the predominant form of dementia. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

A Case of Late‐Onset Semantic Dementia With Right‐Predominant Temporal Lobe Atrophy due to Primary Tauopathy

✓ Peer-reviewed alzhub usefulness score 32 out of 100. Psychogeriatrics 2025-09-01

Semantic dementia (SD) is a type of dementia characterized by a loss of semantic memory, typically presenting with left-predominant temporal lobe atrophy and a frontotemporal lobar degeneration with TDP-43 (FTLD-TDP) type C pathology. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Alismatis Rhizoma prevents AβO-induced neuronal cell death and synaptic loss in Alzheimer’s disease models

✓ Peer-reviewed alzhub usefulness score 32 out of 100. Frontiers in Pharmacology 2026-09-04

In AβO-injected mice, AR, particularly at 200 mg/kg, attenuated memory deficits, reduced hippocampal neuronal degeneration, preserved synaptic protein immunoreactivity and increased markers of hippocampal cell proliferation and immature neurons. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Dysregulation of a novel autophagosome-mitochondria contact contributes to tauopathy-related neurodegeneration by disrupting autophagy

✓ Peer-reviewed alzhub usefulness score 32 out of 100. Autophagy 2026-06-19

Beyond their role in energy production, mitochondria also interact with other organelles through forming membrane contacts that serve as central hubs of cellular metabolism and signaling. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Classification of tauopathies from human brain homogenates through salt-modulated tau amplification

✓ Peer-reviewed alzhub usefulness score 32 out of 100. Apollo (University of Cambridge) 2026-01-15

This method differentiated eight tauopathies, including Alzheimer's disease, Pick disease, progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), argyrophilic grain disease (AGD), frontotemporal dementia with parkinsonism associated with chromosome 17 with N279K mutation (FTDP-17 N279K), and globular glial tauopathies types II and III. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Cell type- and tau lesion-specific accumulation of phospho-Ser65 ubiquitin in primary tauopathies

✓ Peer-reviewed alzhub usefulness score 32 out of 100. Acta Neuropathologica Communications 2026-09-04

Defective mitochondrial quality control is increasingly implicated in tau-mediated neurodegeneration, but how distinct tau lesions in different cell types interact with PINK1-PRKN-mediated mitophagy remains unclear. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

A review on recent advances in Alzheimer's disease: The role of synaptic plasticity

✓ Peer-reviewed alzhub usefulness score 32 out of 100. AIMS neuroscience 2025-01-01

Alzheimer's Disease (AD) remains a significant global health challenge, characterized by progressive neurodegeneration and a decline in cognitive abilities such as memory and learning. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Implications of virus-induced stress granules in tauopathies

✓ Peer-reviewed alzhub usefulness score 31 out of 100. Translational Neurodegeneration 2026-02-12

Tauopathies are characterized by aberrant tau structure and function, which is associated with neurodegenerative dementias, such as Alzheimer's disease, Pick's disease, and frontotemporal dementia, as well as the motor neuron disease amyotrophic lateral sclerosis. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Altered Membrane Protein Abundance in the Cerebral Cortex of the JNPL3 Mouse Model of Tauopathy

✓ Peer-reviewed alzhub usefulness score 31 out of 100. Journal of Proteome Research 2026-09-16

In addition, we found sex-associated changes in the abundances of several proteins previously reported to be involved in tau pathology, such as Reelin, DARPP-32, Zyxin, Tbce, and Gng5, in JNPL3 mice. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Relationship between Alzheimer's Disease and Type 2 Diabetes: Critical Review On Cellular and Molecular Common Pathogenic Mechanisms

✓ Peer-reviewed alzhub usefulness score 31 out of 100. Current Alzheimer Research 2025-02-01

Both diseases exhibit common genetic, epigenetic, biochemical and physiological characteristics. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed